Evaluation of serum anti-Mullerian hormone levels to assess the ovarian reserve in women with severe endometriosis

Pacchiarotti, Arianna; Frati, Paola; Milazzo, G.; Catalano, Angelica; Gentile, Vincenzo; Mangino, Massimo

doi:10.1016/j.ejogrb.2013.10.003

Cited by 42 publications

(30 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…So AMH could be used in the follow-up of patients with endometriosis, in order to assess promptly the decrease of ovarian reserve. 34 In conclusion from findings of this small study it can be said that endometrioma itself might be associated with poor ovarian reserve of this population. So care should be taken for subsequent treatment plan and approach of surgery so that fertility prospect is not lost by treatment itself.…”

Section: Discussionmentioning

confidence: 66%

“…Remarkable declines in serum AMH were reported in patients with moderate to sever endometriosis, which was more pronounced in those with bilateral endometrioma. 25,[31][32][33][34][35][36] Ovaries with endometrioma may already have some damage with decreased ovarian reserve. [24][25][26] Lower anti-mullerian hormone serum levels and association with the severity of the disease found in women with endometriosis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Endometrioma is a Responsible Factor for Reduced Ovarian Reserve

Begum

Ehsan²,

Ehsan³

et al. 2016

Bangladesh J Obstet Gynaecol

View full text Add to dashboard Cite

Objective (s): The aim of the study was to assess ovarian reserve (OR) of patients with endometrioma and to explore the differences of ovarian reserve in age matched group of infertile patients without endometrioma.Materials and methods: This prospective analytic study was done in Infertility Care and Research Center, between January 2013 and December 2015 to assess the ovarian reserve of patients with endometrioma. During this period 105 patients of endometriosis with endometrioma were selected for study. Selection criteria were: no history of previous surgery, <36 years of age, no history of endocrine problems, no history of recent medical treatment for this condition within 6 months and no history of irregular menstruation. For ovarian reserve testing we assessed serum FSH, E2 and AMH. Patient of same age group who had no emdometrioma, no history of any surgery, no menstrual irregularity, endocrine disorder or any other medical diseases were taken as control to compare the ovarian reserve between these two groups. For control group also we did the same tests. Data was analyzed by SPSS package. One-way ANOVA test was done for test of significance. A p-value of <0.05 was considered as significant.Results: There was no difference in characteristics of patients of both groups regarding age, type of infertility and duration of infertility. Size of the endometriotic cysts were variable and average diameter of cyst was 6.2 ±2.32 cm. Most (58.10%) of the cysts were unilateral. There is a significant difference of FSH and AMH level between the groups. FSH of endometrioma and non-endometrioma group was 7.9 ±1.17 and 7.1 ±1.05 mIU/mL respectively with a p value of 0.029. Similar difference was present in AMH level, which was 2.42 ±.63 and 2.98 ±.88 ng/ mL in endometrioma and non-endometrioma group respectively with a p value of 0.020.Conclusion: This small study shows a reduced ovarian reserve in patients with endometrioma in comparison to patients of same parameters without endometrioma. It suggests that there is an association of presence of ovarian endometrioma and reduced ovarian reserveBangladesh J Obstet Gynaecol, 2015; Vol. 30(2) : 98-104

show abstract

Section: Discussionmentioning

confidence: 66%

Section: Discussionmentioning

confidence: 99%

Endometrioma is a Responsible Factor for Reduced Ovarian Reserve

Begum

Ehsan²,

Ehsan³

et al. 2016

Bangladesh J Obstet Gynaecol

View full text Add to dashboard Cite

show abstract

“…Средний показатель уровня гормонов ФСГ, антимюллерова гормона (АМГ), ингибина В, активина А не имел су-щественных изменений относительно контроля. По-лученные результаты не противоречат данным лите-ратуры [6][7][8][9], в которых отмечено, что наличие эн-дометриомы размером менее 3 см не влияет на уро-вень овариального резерва.…”

Section: результаты и обсуждениеunclassified

Results of conservative treatment of endometriomas

Клинышкова¹,

Perfilieva²,

Soveyko³

2015

Probl. reprod.

View full text Add to dashboard Cite

“…The understanding of AMH and endometriosis continue to develop, with a recent report indicating AMH may actually play a role in endometriosis [70]. Although some consider endometrioma removal as important for improving fertility [71], clear evidence demonstrates serum AMH is lowered by ovarian surgeries such as removing cysts and endometriomas [72 ▪ ,73 ▪▪ ,74–76].…”

Section: Association With Other Disorders: Autoimmunity Granulosa Cementioning

confidence: 99%

“…Some of these studies have demonstrated that AMH testing can improve treatment selection by identifying which therapies are most toxic to the ovary and which patients are most at risk for postchemotherapy ovarian insufficiency [77 ▪ ,78 ▪▪ ,79–84]. Furthermore, numerous reports are confirming that after some ovarian-related surgeries such as removal of benign cysts and endometriomas, significant reductions in AMH are observed which may persist [72 ▪ ,73 ▪▪ ,74–76] with a recent study demonstrating similar reductions with benign cysts and endometriomas and more severe reductions with bilateral procedures [85]. Interestingly, one report shows only transient reductions in AMH in 22 PCOS patients undergoing the more minor procedure of ovarian puncture [86].…”

Section: Monitoring Ovarian Damage With Medical Therapies and Surgicamentioning

confidence: 99%

Maximizing the clinical utility of antimüllerian hormone testing in women's health

Leader¹,

Baker

2014

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Purpose of reviewTo provide an update on the latest clinical applications of serum antimüllerian hormone (AMH) testing with practical approaches to mitigate the impact of significant variability in AMH results.Recent findingsRecent studies continue to demonstrate that AMH is the best single serum test for ovarian response management with, at most, a weak-to-moderate age-independent association with live-birth rate and time to conception. Data confirm serum AMH levels improve menopause prediction, monitoring of ovarian damage, and identification of women at risk for several ovary-related disorders such as polycystic ovary syndrome and premature or primary ovarian insufficiency. However, it is now recognized that serum AMH results can have dramatic variability due to common, biologic fluctuations within some individuals, use of hormonal contraceptives or other medications, certain surgical procedures, specimen treatment, assay changes, and laboratory calibration differences. Practical guidelines are provided to minimize the impact of variability in AMH results and maximize the accuracy of clinical decision-making.SummaryAMH is an ovarian biomarker of central importance which improves the clinical management of women's health. However, with the simultaneous rapid expansion of AMH clinical applications and recognition of variability in AMH results, consensus regarding the clinical cutpoints is increasingly difficult. Therefore, a careful approach to AMH measurement and interpretation in clinical care is essential.

show abstract

Evaluation of serum anti-Mullerian hormone levels to assess the ovarian reserve in women with severe endometriosis

Cited by 42 publications

References 36 publications

Endometrioma is a Responsible Factor for Reduced Ovarian Reserve

Endometrioma is a Responsible Factor for Reduced Ovarian Reserve

Results of conservative treatment of endometriomas

Maximizing the clinical utility of antimüllerian hormone testing in women's health

Contact Info

Product

Resources

About